Sign In
Last checked at 
16 Sep 2015 16:08
ο»Ώ
Β
Β
Β
Β
Β
Hikma Pharmaceuticals PLC
Voting Rights and Capital
Β
LONDON, 16 September 2015, Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) notifies the market that its capital consists of 199,339,621 ordinary shares with voting rights. There are nil shares held in treasury.
Β
The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Hikma Pharmaceuticals PLC under the FCA's Disclosure and Transparency Rules.
Β
- ENDS -
Β
Enquiries
Β
Hikma Pharmaceuticals PLC | Β | |
Peter Speirs Company Secretary Β | +44 20 7399 2760 Β | |
Β | ||
Β
About Hikma
Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2014, Hikma achieved revenues of $1,489 million and profit attributable to shareholders of $278 million.
Β
Follow the stocks
